Review
doi: 10.1177/1073858405280639.
The ubiquitin-proteasome system in Huntington's disease
Affiliations
- PMID: 16282599
- DOI: 10.1177/1073858405280639
Item in Clipboard
Review
The ubiquitin-proteasome system in Huntington's disease
Neuroscientist.
2005 Dec.
Abstract
The main histopathological feature of Huntington's disease (HD) is the presence of protein aggregates that are gathered into inclusion bodies. So far the mechanisms that lead to inclusion formation as well as their role in the pathogenesis of HD are not totally understood. However, it is well established that inclusion bodies contain components of the ubiquitin-proteasome system. Accordingly, it has been postulated that impairment of this machinery can be one of the causes of this disorder. In this review, the authors summarize the state of current knowledge about this hypothesis.
Similar articles
-
Global changes to the ubiquitin system in Huntington's disease.Nature. 2007 Aug 9;448(7154):704-8. doi: 10.1038/nature06022. Nature. 2007. PMID: 17687326
-
Inhibition of 26S proteasome activity by huntingtin filaments but not inclusion bodies isolated from mouse and human brain.J Neurochem. 2006 Sep;98(5):1585-96. doi: 10.1111/j.1471-4159.2006.03968.x. Epub 2006 Jun 19. J Neurochem. 2006. PMID: 16787406
-
Proteasome impairment does not contribute to pathogenesis in R6/2 Huntington's disease mice: exclusion of proteasome activator REGgamma as a therapeutic target.Hum Mol Genet. 2006 Jan 1;15(1):33-44. doi: 10.1093/hmg/ddi423. Epub 2005 Nov 25. Hum Mol Genet. 2006. PMID: 16311253
-
The ubiquitin-proteasome pathway in Parkinson's disease and other neurodegenerative diseases.Trends Cell Biol. 2004 Dec;14(12):703-11. doi: 10.1016/j.tcb.2004.10.006. Trends Cell Biol. 2004. PMID: 15564047 Review.
-
Ubiquitin proteasome system as a pharmacological target in neurodegeneration.Expert Rev Neurother. 2006 Sep;6(9):1337-47. doi: 10.1586/14737175.6.9.1337. Expert Rev Neurother. 2006. PMID: 17009921 Review.
Cited by
-
A Critical Evaluation of Wet Biomarkers for Huntington's Disease: Current Status and Ways Forward.J Huntingtons Dis. 2018;7(2):109-135. doi: 10.3233/JHD-170273. J Huntingtons Dis. 2018. PMID: 29614689 Free PMC article. Review.
-
Alternations of Lipoprotein Profiles in the Plasma as Biomarkers of Huntington's Disease.Cells. 2023 Jan 20;12(3):385. doi: 10.3390/cells12030385. Cells. 2023. PMID: 36766727 Free PMC article.
-
Huntington's disease (HD): degeneration of select nuclei, widespread occurrence of neuronal nuclear and axonal inclusions in the brainstem.Brain Pathol. 2014 Apr;24(3):247-60. doi: 10.1111/bpa.12115. Epub 2014 Mar 3. Brain Pathol. 2014. PMID: 24779419 Free PMC article.
-
Diagnostic Potential of Alternations of Bile Acid Profiles in the Plasma of Patients with Huntington's Disease.Metabolites. 2024 Jul 20;14(7):394. doi: 10.3390/metabo14070394. Metabolites. 2024. PMID: 39057717 Free PMC article.
-
Neuroprotection for Huntington's disease: ready, set, slow.Neurotherapeutics. 2008 Apr;5(2):226-36. doi: 10.1016/j.nurt.2008.01.003. Neurotherapeutics. 2008. PMID: 18394565 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
